Want to see ONCY full AI Analyst Report?
ONCY Stock Chart & Stats
$0.86
-$0.01(-1.50%)
At close: 4:00 PM EDT
$0.86
-$0.01(-1.50%)
Day’s Range― - ―
52-Week Range$0.64 - $1.47
Previous CloseN/A
Volume317.18K
Average Volume (3M)937.53K
Market Cap
$86.01M
Enterprise Value$110.07
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$448.00K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Oct 30, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding127,510,506
10 Day Avg. Volume1,079,281
30 Day Avg. Volume937,533
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-22.05
Price to Sales (P/S)0.00
P/FCF Ratio-5.71
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside481.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Broad Immuno-oncology MechanismPelareorep’s ability to alter a suppressive tumor microenvironment supports a differentiated mechanism beyond direct tumor killing. If reproduced clinically, this could make multiple treatments more effective and broaden the candidate’s relevance across difficult solid-tumor settings.
FDA-aligned Registrational PathwayRegulatory clarity can reduce development uncertainty and help the company design a more efficient path from randomized Part A data to a pivotal expansion. A credible approval framework may also improve partnering leverage if clinical results validate the approach.
Clinical And Regulatory Momentum In GI CancersFast Track designation and reported activity in a high-need gastrointestinal cancer setting provide external validation for pelareorep’s development strategy. Progress across more than one GI indication could diversify clinical opportunities and strengthen the pipeline’s strategic value.
Bears Say
No Reported Revenue And Widening LossesThe company remains dependent on advancing an investigational therapy rather than generating product revenue, while losses are increasing. This weak profitability trajectory limits internally funded investment and makes future progress more reliant on financing, partnerships, or milestone receipts.
Persistent And Increasing Cash BurnSustained negative cash flow means ongoing clinical development consumes substantial resources without corresponding operating inflows. The worsening burn rate can shorten financial runway and increase the likelihood that additional capital will be needed before meaningful clinical or commercial milestones are reached.
Negative Equity And Shrinking Asset BaseNegative equity and a materially smaller asset base indicate substantial balance-sheet deterioration and reduced financial flexibility. This weakens the company’s ability to absorb setbacks or fund trials internally, potentially increasing dependence on external capital and dilutive financing.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.64 and its highest was $1.47 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $86.01M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Oct 30, 2026 which is in 29 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Aug 12, 2026. The company reported -$0.078 earnings per share for the quarter, missing the consensus estimate of -$0.053 by -$0.025.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.05.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 127,510,506 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.078 in its last earnings report, missing expectations of -$0.053. Following the earnings report the stock price went down -2.795%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncolytics Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (481.40% Upside)
$5.00 (481.40% Upside)
Blogger Sentiment
Bullish
ONCY Sentiment 100%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 11.8%
Last 30 Days ▲ 11.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-45.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY Stock 12 Month Forecast
Average Price Target
$5.00
▲(481.40% Upside)
Technical Analysis
Atossa Therapeutics
―
Oramed Pharm
―
Atara Biotherapeutics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―